Skip to content
Journal ArticleAlzheimer's & dementia (Amsterdam, Netherlands)·Graded and published ·Last edited

Semaglutide Slows the Rise of a Dementia Risk Score in Blood

Graded Moderate — a later analysis of a large trial with random assignment, 2,970 people and 104 weeks; it measured a predicted risk, not actual dementia cases.

Design
Randomized controlled trial
Participants
2,970
Duration
2 years
Funding
Two authors are employees and shareholders of the drug maker Novo Nordisk, and…
Key Insight

In older adults on semaglutide, a blood score for predicted dementia risk rose more slowly than with a dummy injection.


A blood test can estimate dementia risk over the next five and twenty years by reading 25 proteins. In older adults who received semaglutide, that estimated risk rose more slowly than in those who got a dummy injection. Semaglutide is a GLP-1 drug injected once a week.

The data come from the large SELECT trial. It included 2,970 adults aged 65 or older with overweight or obesity and heart or blood vessel disease, but no diabetes. They were chosen at random to get semaglutide or a dummy injection. Researchers tested their blood at the start and after 104 weeks. With semaglutide, the predicted five-year dementia risk rose two and a half times less. Participants were also less often moved into a higher risk category.

The study did not count who actually developed dementia. It measured a predicted risk. Whether semaglutide prevents dementia cases cannot be read from these results. The analysis was also planned only after the trial.

Conflict of Interest Disclosure: Two authors are employees and shareholders of the drug maker Novo Nordisk, and one author received fees from companies including Novo Nordisk.

Disclaimer: Research summaries are provided for informational purposes only and do not constitute medical advice. Always consult a qualified healthcare professional before making changes to your health routine.